320 related articles for article (PubMed ID: 31631040)
1. Accumulation of mitochondrial 7S DNA in idiopathic and LRRK2 associated Parkinson's disease.
Podlesniy P; Puigròs M; Serra N; Fernández-Santiago R; Ezquerra M; Tolosa E; Trullas R
EBioMedicine; 2019 Oct; 48():554-567. PubMed ID: 31631040
[TBL] [Abstract][Full Text] [Related]
2. Cell-free mitochondrial DNA deletions in idiopathic, but not LRRK2, Parkinson's disease.
Puigròs M; Calderon A; Pérez-Soriano A; de Dios C; Fernández M; Colell A; Martí MJ; Tolosa E; Trullas R
Neurobiol Dis; 2022 Nov; 174():105885. PubMed ID: 36208866
[TBL] [Abstract][Full Text] [Related]
3. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.
Howlett EH; Jensen N; Belmonte F; Zafar F; Hu X; Kluss J; Schüle B; Kaufman BA; Greenamyre JT; Sanders LH
Hum Mol Genet; 2017 Nov; 26(22):4340-4351. PubMed ID: 28973664
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial DNA in CSF distinguishes LRRK2 from idiopathic Parkinson's disease.
Podlesniy P; Vilas D; Taylor P; Shaw LM; Tolosa E; Trullas R
Neurobiol Dis; 2016 Oct; 94():10-7. PubMed ID: 27260835
[TBL] [Abstract][Full Text] [Related]
5. Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.
Agalliu I; Ortega RA; Luciano MS; Mirelman A; Pont-Sunyer C; Brockmann K; Vilas D; Tolosa E; Berg D; Warø B; Glickman A; Raymond D; Inzelberg R; Ruiz-Martinez J; Mondragon E; Friedman E; Hassin-Baer S; Alcalay RN; Mejia-Santana H; Aasly J; Foroud T; Marder K; Giladi N; Bressman S; Saunders-Pullman R
Mov Disord; 2019 Sep; 34(9):1392-1398. PubMed ID: 31348549
[TBL] [Abstract][Full Text] [Related]
6. Exhaustion of mitochondrial and autophagic reserve may contribute to the development of LRRK2
Juárez-Flores DL; González-Casacuberta I; Ezquerra M; Bañó M; Carmona-Pontaque F; Catalán-García M; Guitart-Mampel M; Rivero JJ; Tobias E; Milisenda JC; Tolosa E; Marti MJ; Fernández-Santiago R; Cardellach F; Morén C; Garrabou G
J Transl Med; 2018 Jun; 16(1):160. PubMed ID: 29884186
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial Mechanisms of LRRK2 G2019S Penetrance.
Delcambre S; Ghelfi J; Ouzren N; Grandmougin L; Delbrouck C; Seibler P; Wasner K; Aasly JO; Klein C; Trinh J; Pereira SL; Grünewald A
Front Neurol; 2020; 11():881. PubMed ID: 32982917
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson's disease patient fibroblasts.
Korecka JA; Thomas R; Christensen DP; Hinrich AJ; Ferrari EJ; Levy SA; Hastings ML; Hallett PJ; Isacson O
Hum Mol Genet; 2019 Oct; 28(19):3232-3243. PubMed ID: 31261377
[TBL] [Abstract][Full Text] [Related]
9. LRRK2 activation in idiopathic Parkinson's disease.
Di Maio R; Hoffman EK; Rocha EM; Keeney MT; Sanders LH; De Miranda BR; Zharikov A; Van Laar A; Stepan AF; Lanz TA; Kofler JK; Burton EA; Alessi DR; Hastings TG; Greenamyre JT
Sci Transl Med; 2018 Jul; 10(451):. PubMed ID: 30045977
[TBL] [Abstract][Full Text] [Related]
10. Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease.
Arora S; Visanji NP; Mestre TA; Tsanas A; AlDakheel A; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Lang AE; Little MA; Marras C
J Parkinsons Dis; 2018; 8(4):503-510. PubMed ID: 30248062
[TBL] [Abstract][Full Text] [Related]
11. Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers.
Dzamko N; Rowe DB; Halliday GM
Mov Disord; 2016 Jun; 31(6):889-97. PubMed ID: 26917005
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial Calcium Dysregulation Contributes to Dendrite Degeneration Mediated by PD/LBD-Associated LRRK2 Mutants.
Verma M; Callio J; Otero PA; Sekler I; Wills ZP; Chu CT
J Neurosci; 2017 Nov; 37(46):11151-11165. PubMed ID: 29038245
[TBL] [Abstract][Full Text] [Related]
13. A blood-based marker of mitochondrial DNA damage in Parkinson's disease.
Qi R; Sammler E; Gonzalez-Hunt CP; Barraza I; Pena N; Rouanet JP; Naaldijk Y; Goodson S; Fuzzati M; Blandini F; Erickson KI; Weinstein AM; Lutz MW; Kwok JB; Halliday GM; Dzamko N; Padmanabhan S; Alcalay RN; Waters C; Hogarth P; Simuni T; Smith D; Marras C; Tonelli F; Alessi DR; West AB; Shiva S; Hilfiker S; Sanders LH
Sci Transl Med; 2023 Aug; 15(711):eabo1557. PubMed ID: 37647388
[TBL] [Abstract][Full Text] [Related]
14. Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease.
Marras C; Alcalay RN; Caspell-Garcia C; Coffey C; Chan P; Duda JE; Facheris MF; Fernández-Santiago R; Ruíz-Martínez J; Mestre T; Saunders-Pullman R; Pont-Sunyer C; Tolosa E; Waro B;
Mov Disord; 2016 Aug; 31(8):1192-202. PubMed ID: 27091104
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease.
Gonzalez-Hunt CP; Thacker EA; Toste CM; Boularand S; Deprets S; Dubois L; Sanders LH
Sci Rep; 2020 Oct; 10(1):17293. PubMed ID: 33057100
[TBL] [Abstract][Full Text] [Related]
16. Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.
Mestre TA; Pont-Sunyer C; Kausar F; Visanji NP; Ghate T; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Kasten M; Wadia PM; Zadikoff C; Kumar P; de Bie RM; Thomsen T; Lang AE; Schüle B; Klein C; Tolosa E; Marras C
Mov Disord; 2018 Jul; 33(6):960-965. PubMed ID: 29665080
[TBL] [Abstract][Full Text] [Related]
17. LRRK2 maintains mitochondrial homeostasis and regulates innate immune responses to
Weindel CG; Bell SL; Vail KJ; West KO; Patrick KL; Watson RO
Elife; 2020 Feb; 9():. PubMed ID: 32057291
[TBL] [Abstract][Full Text] [Related]
18. Comparative blood transcriptome analysis in idiopathic and LRRK2 G2019S-associated Parkinson's disease.
Infante J; Prieto C; Sierra M; Sánchez-Juan P; González-Aramburu I; Sánchez-Quintana C; Berciano J; Combarros O; Sainz J
Neurobiol Aging; 2016 Feb; 38():214.e1-214.e5. PubMed ID: 26675812
[TBL] [Abstract][Full Text] [Related]
19. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.
Liu SY; Wile DJ; Fu JF; Valerio J; Shahinfard E; McCormick S; Mabrouk R; Vafai N; McKenzie J; Neilson N; Perez-Soriano A; Arena JE; Cherkasova M; Chan P; Zhang J; Zabetian CP; Aasly JO; Wszolek ZK; McKeown MJ; Adam MJ; Ruth TJ; Schulzer M; Sossi V; Stoessl AJ
Lancet Neurol; 2018 Apr; 17(4):309-316. PubMed ID: 29456161
[TBL] [Abstract][Full Text] [Related]
20. Differential Phospho-Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease.
Garrido A; Santamaría E; Fernández-Irigoyen J; Soto M; Simonet C; Fernández M; Obiang D; Tolosa E; Martí MJ; Padmanabhan S; Malagelada C; Ezquerra M; Fernández-Santiago R
Mov Disord; 2022 May; 37(5):1004-1015. PubMed ID: 35049090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
